AR063458A1 - Derivados de piridina inhibidores de 11beta hsd1 - Google Patents

Derivados de piridina inhibidores de 11beta hsd1

Info

Publication number
AR063458A1
AR063458A1 ARP070104887A ARP070104887A AR063458A1 AR 063458 A1 AR063458 A1 AR 063458A1 AR P070104887 A ARP070104887 A AR P070104887A AR P070104887 A ARP070104887 A AR P070104887A AR 063458 A1 AR063458 A1 AR 063458A1
Authority
AR
Argentina
Prior art keywords
alkyl
ring
independently selected
halo
cyano
Prior art date
Application number
ARP070104887A
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR063458A1 publication Critical patent/AR063458A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Abstract

Reivindicacion 1: Un compuesto de formula (1):en el cual: Q es un enlace simple, -O-, -S- o -N(R15)-, donde R15 es hidrogeno, alquilo C1-3 o alcanoilo C2-3 o R15 y R1 junto con el átomo de nitrogeno al cual están unidos forman un anillo saturado de 4-7 miembros; R1 es alquilo C1-6, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, cicloalquil C3-7-alquilo C1-3, cicloalquil C3-7-alquenilo C2-3, cicloalquil C3-7-alquinilo C2-3, fenilo, fenilalquilo C1-3, heteroarilo, heteroarilalquilo C1-3, heterociclilo, o heterociclilalquilo C1-3 [cada uno de los cuales está sustituido en forma opcional con 1, 2 o :3 sustituyentes seleccionados en forma independiente de alquilo C1-3, hidroxi, halo, oxo, ciano, trifluorometilo, alcoxi C1-3, carboxialquilo C1-3, alquil C1-3S(O)n- (donde n es 0, 1, 2 o 3), R5CON(R5')-, (R5')(R5ö)NC(O)-, R5'C(O), R5OC(O)- y (R5')(R5ö)NSO2- (donde R5 es alquilo C1-3 sustituido nn forma opcional con 1, 2 o 3 sustituyentes seleccionados en forma independiente de hidroxilo, halo y ciano); y R5' y R5ö se seleccionan en forma independiente de hidrogeno y alquilo C1-3 sustituido en forma opcional con 1, 2 o 3 sustituyentes seleccionados en forma independiente de hidroxilo, halo, alcoxi C1-3, carboxi y ciano o R5' y R5ö junto con el átomo de nitrogeno al cual están unidos forman un anillo saturado de 4-7 miembros)] y los sustituyentes opcionales para el heterociclilo y el guipo heterociclilo en heterociclilalquilo C1-3 se seleccionan en forma adicional de R21, R21CO-R21S(O)k, (donde k es 0, 1 o 2) y R21CH2OC(O)- donde R21 es fenilo sustituido en forma opcional con 1 o 2 sustituyentes seleccionados en forma independiente de halo, hidroxi, ciano y trifluorometilo; o cuando Q es un enlace R1 puede también ser hidrogeno; R2 se selecciona de cicloalquil C3-7(CH2)m,- y policicloalquil C6-12(CH2)m- (donde los anillos cicloalquilo y policicloalquilo contienen en forma opcional 1 o 2 átomos en el anillo seleccionados en forma independiente de nitrogeno, oxigeno y azufre; m es 0, 1 o 2 y los anillos están sustituidos en forma opcional con 1, 2 o 3 sustituyentes seleccionados en forma independiente de R6); R3 se selecciona de hidrogeno, alquil C1-4-cicloalquilo C3-5 y cicloalquil C3-5-metilo; R2 y R3 junto con el átomo de nitrogeno al cual están unidos forman un sistema anular en puente, mono o bicíclico saturado que contiene en forma opcional 1 o 2 heteroátomos anulares adicionales seleccionados de nitrogeno, oxigeno y azufre y que está fusionado en forma opcional a un anillo saturado parcialmente saturado o insaturado, monocíclico, donde el sistema anular resultante está sustituido en forma opcional con 1, 2. o 3 sustituyentes seleccionados en forma independiente de R7; R4 se selecciona en forma independiente de halo, alquilo C1-2, ciano, alcoxi C1-2 y trifluorometilo; R6 y R7 se seleccionan en forma independiente de hidroxilo, halo, oxo, carboxi, ciano, trifluorometilo, R9, R9O-, R9CO-, R9C(O)O-, R9CON(R9')-, (R9')(R9ö)NC(O)-, (R9')(R9ö)N-, R9S(O)a-, donde a es 0 hasta 2, R9'OC(O)-, (R9')(R9ö)NSO2-, R9SO2N(R9')-, (R9')(R9ö)NC(O)N(R9ö)-, fenilo y heteroarilo [donde los grupos fenilo y heteroarilo están fusionados en forma opcional a un fenilo, heteroarilo o un anillo de 5 o 6 miembros saturado o parcialmente saturado que contiene en forma opcional 1, 2 o 3 heteroátomos seleccionados en forma independiente de nitrogeno, oxigeno y azufre y el sistema anular resultante está sustituido en forma opcional con 1, 2 o 3 sustituyentes seleccionados en forma independiente de alquilo C1-4, hidroxilo, ciano, trifluorometilo, trifluorometoxi, halo, alcoxi C1-4, alcoxi C1-4-alquilo C1-4, alcoxi C1-4-aIquilo C1-4, amino, N- alquilamino C1-4, di-N,N-(alquil C1-4)amino, N-alquilcarbamoilo C1-4, di-N,N-(alquil C1-4)carbamoílo, alquil C1-4S(O)r-, alquil C1-4S(O)r-alquilo C1-4 (donde r es 0, 1 y 2)];R9 es en forma independiente alquilo C1-3 suslituido en forma opcional con 1, 2 o 3 sustituyentes seleccionados en forma independiente de hidroxilo, halo, alcoxi C1-4, carboxi y ciano; R9', R9ö y 9'öse seleccionan en forma independiente de hidrogeno y alquilo C1-3 sustituido en forma opcional con hidroxilo, halo, alcoxi C1- 4, carboxi o ciano; p es 0, 1 o 2; cualquier X es -O(CH2)q-, S(CH2)q- o -N(R12)(CH2)q-, donde R12 es hidrogeno, alquilo C1-3 o alcanoilo C1-3 y q es 0 o 1; e Y es: 1) un anillo cicloalquidilo C3-7, un anillo fenileno, un grupo adamantidilo, un anillo heterociclilo saturado de 5-7 miembros (conectado por un átomo de carbono del anillo) que contiene 1 o 2 heteroátomos en el anillo seleccionados nitrogeno, oxígeno y azufre, o -[C(Rx)(Ry)]v- (donde Rx y Ry se seleccionan en forma independiente de hidrogeno, alquilo C1-3, alcoxi C1-3 e hidroxilo o Rx y Ry junto con el átomo de carbono al cual están unidos forman un anillo cicloalquidilo C3-7 y v es 1, 2, 3, 4 o 5) y cuando y es mayor que 1 el grupo [C(Rx)(Ry)]v- puede estar interrumpido en forma opcional por un grupo -O-, -S- o -N(R20)-, donde R20 es hidrogeno o alquilo C1-3; o 2) -X-Y- juntos representan un grupo de formula (2) en el cual el anillo A está conectado con el grupo piridina y (Z)t[C(R13)(R14)]s- está conectado con el grupo carboxi; y A es un sistema anular mono-, bi- o espiro-heterocíclico de 4-7 miembros que contiene un átomo de nitrogeno del anillo por el cual está unido al anillo de piridina y en forma adicional y opcional otro heteroátomo del anillo seleccionado de nitrogeno, oxígeno y azufre; Z es -O-, -S- o -N(R16)- donde R16 es hidrogeno, alquilo C1-3 o alcanoilo C1-3; t es 0 o 1 siempre que cuando s es 0 entonces t es 0; R10 se selecciona en forma independiente de alquilo C1-3, alquenilo C2-3, alquinilo C2-3, hidroxi, halo, oxo, ciano, trifluorometilo alcoxi C1-3, alquil C1-3S(O)n- (donde n es 0, 1, 2 o 3), R11CON(R 11'), (R11')(R11ö)NC(O)-, R11'OC(O)- y (R11')(R11ö)NSO2- (donde R11 es alquilo C1-3 sustituido en forma opcional con hidroxilo, halo o ciano; y R11' y R11ö se seleccionan en forma independiente de hidrogeno y alquilo C1-3 sustituido en forma opcional con hidroxilo, halo, alcoxi C1-3, carboxi o ciano) o R11' y R11ö junto con el átomo de nitrogeno al cual están unidos forman un anillo de 4-7 miembros; u es 0, 1 o 2; R13 y R14 se seleccionan en forma independiente de hidrogeno y alquilo C1-3 o R13 y R14 pueden formar, junto con el átomo de carbono al cual están unidos, un anillo cicloalquilo C3- 7; y s es 0, 1 o 2; o una de sus sales o sus ésteres hidrolizables in vivo aceptable desde el punto de vista farmacéutico; siempre que el compuesto no sea: ácido {(3S)-1-[5-(adamantan-1-ilcarbamoil)piridin-2-il]piperidin-3-il}acético; o ácido {(3S)- 1-[5-(ciclohexilcarbamoil)-6-(piperazin-1-il)piridin-2-il]piperidin-3-il}acético; o una de sus sales o sus ésteres hidrolizables in vivo aceptables desde el punto de vista farmacéutico.
ARP070104887A 2006-11-03 2007-11-02 Derivados de piridina inhibidores de 11beta hsd1 AR063458A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US86424706P 2006-11-03 2006-11-03
US86430306P 2006-11-03 2006-11-03

Publications (1)

Publication Number Publication Date
AR063458A1 true AR063458A1 (es) 2009-01-28

Family

ID=39304797

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070104887A AR063458A1 (es) 2006-11-03 2007-11-02 Derivados de piridina inhibidores de 11beta hsd1

Country Status (31)

Country Link
US (3) US7964618B2 (es)
EP (2) EP2086939B8 (es)
JP (1) JP5165688B2 (es)
KR (1) KR101465275B1 (es)
CN (3) CN101573336B (es)
AR (1) AR063458A1 (es)
AT (1) ATE475649T1 (es)
AU (1) AU2007315955B2 (es)
BR (1) BRPI0717970C1 (es)
CA (1) CA2668006C (es)
CL (1) CL2007003176A1 (es)
CO (1) CO6321130A2 (es)
CY (1) CY1110813T1 (es)
DE (1) DE602007008137D1 (es)
DK (1) DK2086939T3 (es)
ES (2) ES2423206T3 (es)
HK (1) HK1135090A1 (es)
HR (1) HRP20100522T1 (es)
IL (1) IL198231A0 (es)
MX (1) MX2009004707A (es)
NO (1) NO20091603L (es)
NZ (1) NZ576501A (es)
PE (1) PE20081487A1 (es)
PL (1) PL2086939T3 (es)
PT (1) PT2086939E (es)
RS (1) RS51451B (es)
RU (1) RU2451674C2 (es)
SI (1) SI2086939T1 (es)
TW (1) TW200827346A (es)
UY (1) UY30681A1 (es)
WO (1) WO2008053194A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006316087B2 (en) 2005-11-21 2011-03-10 Shionogi & Co., Ltd. Heterocyclic compound having inhibitory activity on 11-beta-hydroxysteroid dehydrogenase type I
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
US8314119B2 (en) 2006-11-06 2012-11-20 Abbvie Inc. Azaadamantane derivatives and methods of use
TW200836719A (en) * 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
BRPI0811191A2 (pt) 2007-05-18 2014-10-29 Shionogi & Co Derivado heterocíclico contendo nitrogênio tendo atividade inibitória para 11beta-hidroxiesteroide deidrogenase tipo 1
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2009051112A1 (ja) * 2007-10-15 2009-04-23 Takeda Pharmaceutical Company Limited アミド化合物およびその用途
WO2009056881A1 (en) * 2007-10-29 2009-05-07 Astrazeneca Ab Chemical compounds 313
KR20100126306A (ko) * 2008-02-04 2010-12-01 아스트라제네카 아베 4-[4-(2-(아다만틸카르바모일)-5-ｔｅｒｔ-부틸-피라졸-1-일]벤조산의 신규한 결정형
CA2719936A1 (en) * 2008-04-22 2009-10-29 Astrazeneca Ab Substituted pyrimidin-5-carboxamides 281
EP2243479A3 (en) 2009-04-20 2011-01-19 Abbott Laboratories Novel amide and amidine derivates and uses thereof
CN102458402B (zh) 2009-06-12 2013-10-02 百时美施贵宝公司 用作激酶调节剂的烟酰胺化合物
UY32954A (es) * 2009-10-20 2011-05-31 Astrazeneca Ab PIRIMIDINAS SUSTITUIDAS CON ADAMANTILIMINOCARBONILO COMO INHIBIDORES DE 11-ß-HSD1 826?.
CA2780908A1 (en) * 2009-11-24 2011-06-03 Allergan, Inc. Novel compounds as receptor modulators with therapeutic utility
US8871208B2 (en) * 2009-12-04 2014-10-28 Abbvie Inc. 11-β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors and uses thereof
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR20110123657A (ko) * 2010-05-07 2011-11-15 에스케이케미칼주식회사 피콜린아마이드 및 피리미딘-4-카복사미드 화합물, 이의 제조방법 및 이를 함유하는 약제학적 조성물
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
SG188307A1 (en) 2010-09-23 2013-04-30 Abbvie Inc Monohydrate of an azaadamantane derivative
US8471027B2 (en) * 2011-04-06 2013-06-25 Hoffmann-La Roche Inc. Adamantyl compounds
EP2735567B1 (en) * 2011-07-21 2016-10-26 Xuanzhu Pharma Co., Ltd. Heterocyclic substituted pyrimidine compound
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN102659657B (zh) * 2012-04-24 2014-08-06 徐州医学院 一种蛋白酶抑制剂pf429242的合成方法
IN2014DN09348A (es) 2012-06-20 2015-07-17 Hoffmann La Roche
IN2014DN09347A (es) 2012-06-20 2015-07-17 Hoffmann La Roche
EP3821892A1 (en) * 2019-11-12 2021-05-19 University of Leeds (s)-2-(1-(5-(cyclohexylcarbamoyl)-6-(propylthio)pyridin-2-yl)piperidin-3-yl) acetic acid for use in treating wounds

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR66581B (es) 1978-02-21 1981-03-27 Delalande Sa
US4734418A (en) 1984-12-14 1988-03-29 Mitsui Petrochemical Industries, Ltd. Quinazoline compounds and antihypertensives
BRPI0014526C1 (pt) 1999-09-16 2021-05-25 Mitsubishi Tanabe Pharma Corp compostos cíclicos de seis elementos contendo nitrogênio aromático, composição farmacêutica e uso do mesmo
FR2803592A1 (fr) * 2000-01-06 2001-07-13 Aventis Cropscience Sa Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant.
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
AU2001288623A1 (en) 2000-09-05 2002-03-22 Tularik, Inc. Fxr modulators
DK1383731T3 (da) 2000-10-20 2009-12-07 Biocryst Pharm Inc Biarylforbindelser som serinproteaseinhibitorer
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
JP2005528395A (ja) 2002-04-05 2005-09-22 ザ ユニバーシティ オブ エディンバラ 組成物
WO2004039795A2 (en) * 2002-10-29 2004-05-13 Fujisawa Pharmaceutical Co., Ltd. Amide compounds for the treatment of hyperlipidemia
TW200503994A (en) * 2003-01-24 2005-02-01 Novartis Ag Organic compounds
SE0300457D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
SE0300458D0 (sv) * 2003-02-19 2003-02-19 Astrazeneca Ab Novel compounds
MXPA05009059A (es) 2003-02-26 2005-10-19 Banyu Pharma Co Ltd Derivados de heteroarilcarbamoilbenceno.
EP1615698B1 (en) 2003-04-11 2010-09-29 High Point Pharmaceuticals, LLC New amide derivatives and pharmaceutical use thereof
CN1832741A (zh) 2003-08-07 2006-09-13 默克公司 作为11－β－羟甾类脱氢酶－1抑制剂的吡唑甲酰胺类
AU2004270733B2 (en) 2003-09-11 2011-05-19 Itherx Pharma, Inc. Cytokine inhibitors
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
WO2005060963A1 (en) 2003-12-19 2005-07-07 Pfizer Inc. Benzenesulfonylamino-pyridin-2-yl derivatives and related compounds as inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 (11-beta-hsd-1) for the treatment of diabetes and obesity
ATE407119T1 (de) 2004-02-24 2008-09-15 Glaxo Group Ltd Pyridinderivate und deren verwendung als modulatoren des cb2-rezeptors
US7423147B2 (en) * 2004-03-31 2008-09-09 Janssen Pharmaceutical, N.V. Pyridine compounds as histamine H3 modulators
MXPA06012831A (es) 2004-05-06 2007-01-26 Pfizer Nuevos compuestos de derivados de morfolina y prolina.
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
PT1763517E (pt) 2004-06-28 2011-07-01 Hoffmann La Roche Derivados de pirimidina como inibidores 11beta-hsd1
JP2008518903A (ja) 2004-11-02 2008-06-05 ファイザー・インク 置換および非置換アダマンチルアミドの新規化合物
WO2006050476A2 (en) 2004-11-03 2006-05-11 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as ion channel modulators and methods of use
EP1846363B1 (en) 2005-01-05 2012-04-25 Abbott Laboratories Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
PL1928840T3 (pl) 2005-04-05 2012-01-31 Hoffmann La Roche 1H-pirazolo-4-karboksyamidy, ich wytwarzanie i ich zastosowanie jako inhibitory dehydrogenazy 11-beta-hydroksysteroidowej
MX2007012213A (es) 2005-04-06 2007-12-10 Hoffmann La Roche Derivados de piridin-3-carboxamida como agonistas inversos de canabinoides.
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
US20060235028A1 (en) 2005-04-14 2006-10-19 Li James J Inhibitors of 11-beta hydroxysteroid dehydrogenase type I
JP2008542247A (ja) 2005-05-24 2008-11-27 アストラゼネカ アクチボラグ グルコキナーゼモジュレーターとしての２−フェニル置換イミダゾール［４，５ｂ］ピリジン／ピラジンおよびプリン誘導体
WO2006132197A1 (ja) 2005-06-07 2006-12-14 Shionogi & Co., Ltd. I型11βヒドロキシステロイド脱水素酵素阻害活性を有するヘテロ環化合物
WO2006132436A1 (ja) 2005-06-08 2006-12-14 Japan Tobacco Inc. 複素環化合物
EA200702498A1 (ru) 2005-06-16 2008-06-30 Пфайзер Инк. N-(пиридин-2-ил)сульфонамидные производные
NZ575514A (en) 2005-07-09 2009-11-27 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
JP2009504621A (ja) 2005-08-09 2009-02-05 アストラゼネカ アクチボラグ 糖尿病の処置のためのヘテロアリールカルバモイルベンゼン誘導体
CA2627813A1 (en) 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted pyrrolones as allosteric modulators of glucokinase
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
AU2006316087B2 (en) 2005-11-21 2011-03-10 Shionogi & Co., Ltd. Heterocyclic compound having inhibitory activity on 11-beta-hydroxysteroid dehydrogenase type I
WO2007089683A1 (en) 2006-01-31 2007-08-09 Incyte Corporation Amido compounds and their use as pharmaceuticals
KR20110007258A (ko) 2006-03-22 2011-01-21 에프. 호프만-라 로슈 아게 11-베타-ｈｓｄ-1로서의 피라졸
BRPI0710669A2 (pt) 2006-04-07 2011-08-16 High Point Pharmaceuticals Llc compostos ativos de dehidrogenase de 11b-hidroxiesteróide tipo 1
JP2009534440A (ja) 2006-04-27 2009-09-24 ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング カリウムチャンネルモジュレーターとしてのｃｂｘカンナビノイド受容体モジュレーターの使用
WO2008012532A2 (en) 2006-07-27 2008-01-31 Astrazeneca Ab : pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
BRPI0811191A2 (pt) 2007-05-18 2014-10-29 Shionogi & Co Derivado heterocíclico contendo nitrogênio tendo atividade inibitória para 11beta-hidroxiesteroide deidrogenase tipo 1
ES2423181T3 (es) 2007-07-17 2013-09-18 F. Hoffmann-La Roche Ag Inhibidores de la 11ß-hidroxiesteroide-deshidrogenasa
US20110060022A1 (en) * 2007-11-06 2011-03-10 Astrazeneca Ab 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]Benzoic Acid - 465
KR20100126306A (ko) 2008-02-04 2010-12-01 아스트라제네카 아베 4-[4-(2-(아다만틸카르바모일)-5-ｔｅｒｔ-부틸-피라졸-1-일]벤조산의 신규한 결정형
CA2719936A1 (en) 2008-04-22 2009-10-29 Astrazeneca Ab Substituted pyrimidin-5-carboxamides 281
EP2391607A1 (en) 2009-01-30 2011-12-07 AstraZeneca AB Novel process for preparing carboxy-containing pyrazoleamido compounds 597
UY32954A (es) * 2009-10-20 2011-05-31 Astrazeneca Ab PIRIMIDINAS SUSTITUIDAS CON ADAMANTILIMINOCARBONILO COMO INHIBIDORES DE 11-ß-HSD1 826?.

Also Published As

Publication number Publication date
UY30681A1 (es) 2008-07-03
CA2668006A1 (en) 2008-05-08
KR101465275B1 (ko) 2014-11-27
CN102603711A (zh) 2012-07-25
PL2086939T3 (pl) 2011-09-30
IL198231A0 (en) 2009-12-24
KR20090075865A (ko) 2009-07-09
PT2086939E (pt) 2010-09-17
CN101787016B (zh) 2013-08-28
CA2668006C (en) 2016-05-24
RS51451B (en) 2011-04-30
US20090312372A1 (en) 2009-12-17
AU2007315955B2 (en) 2011-04-14
US8673938B2 (en) 2014-03-18
HK1135090A1 (en) 2010-05-28
HRP20100522T1 (hr) 2010-11-30
NO20091603L (no) 2009-05-28
TW200827346A (en) 2008-07-01
CN101573336A (zh) 2009-11-04
NZ576501A (en) 2011-03-31
JP5165688B2 (ja) 2013-03-21
ES2423206T3 (es) 2013-09-18
RU2451674C2 (ru) 2012-05-27
SI2086939T1 (sl) 2010-10-29
MX2009004707A (es) 2009-05-15
BRPI0717970C1 (pt) 2021-05-25
CL2007003176A1 (es) 2008-07-25
EP2233480A1 (en) 2010-09-29
JP2010508338A (ja) 2010-03-18
CN101787016A (zh) 2010-07-28
BRPI0717970B8 (pt) 2020-12-01
EP2086939B8 (en) 2011-06-22
EP2086939B1 (en) 2010-07-28
BRPI0717970B1 (pt) 2019-10-22
CN101573336B (zh) 2012-03-21
WO2008053194A3 (en) 2008-10-02
CO6321130A2 (es) 2011-09-20
RU2009115830A (ru) 2010-12-10
BRPI0717970A2 (pt) 2013-11-05
ES2347491T3 (es) 2010-10-29
WO2008053194A2 (en) 2008-05-08
CY1110813T1 (el) 2015-06-10
DK2086939T3 (da) 2010-10-11
EP2086939A2 (en) 2009-08-12
AU2007315955A1 (en) 2008-05-08
EP2233480B1 (en) 2013-05-29
ATE475649T1 (de) 2010-08-15
US20080269288A1 (en) 2008-10-30
US20090306075A1 (en) 2009-12-10
DE602007008137D1 (en) 2010-09-09
US7964618B2 (en) 2011-06-21
PE20081487A1 (es) 2009-01-11

Similar Documents

Publication Publication Date Title
AR063458A1 (es) Derivados de piridina inhibidores de 11beta hsd1
AR074902A1 (es) Derivados de 1,2,4-oxadiazoles agonistas de receptores s1p1
AR053232A1 (es) Derivados de piridina condensadas, composiciones farmaceuticas que los contienen y su empleo en la fabricacion de agentes terapeuticos antiinflamatorios y para el tratamiento de enfermedades relacionadas con el sistema inmunologico.
AR065300A1 (es) Compuestos quimicos derivados de 1,2-pirazol
PE20171177A1 (es) Compuestos aminopirimidinilo inhibidores de jak
AR046244A1 (es) Activadores de glucoquinasa heteroaromaticos de seis miembros 5- sustituidos
KR927003052A (ko) 2-아릴티아졸 유도체 및 그의 약제학적 조성물
AR078168A1 (es) Derivados de piperidinas y piperazinas, procesos para prepararlos y sus usos como moduladores de gpr119
AR056109A1 (es) Derivados de tiazolopiridina como activadores de la actividad de glucoquinasa
AR015765A1 (es) Dihidropirimidinas 2 heterociclicamente sustituidas, proceso para su preparacion, medicamentos que los contienen, proceso para la preparacion de los mismosuso de dichos dihidropirimidinas para la preparacion de un medicamento.
ES2572148T3 (es) Un método para el tratamiento de la enfermedad de Pompe usando 1-desoxinojirimicina y derivados
AR051202A1 (es) Derivados heterociclicos y su uso como inhibidores de la estearoil-coa desaturasa
EA200970493A1 (ru) Макроциклические ингибиторы вируса гепатита с
AR040336A1 (es) Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto
AR055144A1 (es) Inhibidor de secrecion acida
AR047056A1 (es) Derivados de pirimidinas condensadas. composiciones farmacéuticas
RS52397B (en) PYRIDO / 2,1-A / ISOCHINOLINE DERIVATIVES AS DPP-IV INHIBITORS
AR055563A1 (es) Compuestos de piridil acido acetico, agente farmaceutico y utilizacion del compuesto para preparar dicho agente
AR062677A1 (es) Derivados de biaril-sulfonamida, procesos de produccion y composiciones farmaceuticas que los comprenden
PE20140161A1 (es) Compuesto biciclico
AR057770A1 (es) Inhibidores de la p38-map-quinasa y composicion farmaceutica
EA200800484A1 (ru) Макроциклические ингибиторы вируса гепатита с
CA2514191A1 (en) Compound inhibiting dipeptidyl peptidase iv
AR053859A1 (es) Compuestos heterociclicos fusionados
MX2009007954A (es) Derivado de heterocicliden-n-(aril) acetamida.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal